1. Market Research
  2. > Pharmaceutical Market Trends
Physician Views: Can Portola's reversal agent act as growth catalyst for novel anticoagulants?

Physician Views: Can Portola's reversal agent act as growth catalyst for novel anticoagulants?

  • October 2014
  • ID: 3509546
  • Format: PDF
  • Firstword Pharma


Initial Phase III data released by Portola Pharmaceuticals last week appears to have nudged its recombinant Factor Xa antidote andexanet alfa closer to market. The product is designed to be used in patients who have received therapy with a Factor Xa inhibitor, but whom subsequently need the anticoagulant action to be reversed due to bleeding or the requirement for surgery.

Portola's assertion that andexanet alfa will meet demand for a significant unmet need is shared by the FDA, which has granted the drug Breakthrough Therapy status. The regulator is also allowing Portola to submit the compound for approval on the basis of a smaller Phase III study, followed by a larger post-approval confirmatory trial. Analysts expect the compound to reach the market in 2016.

Although the market for Factor Xa inhibitors – comprising Bayer/Johnson & Johnson's Xarelto, Daiichi Sankyo's Edoxaban and Bristol-Myers Squibb/Pfizer's Eliquis – has rapidly achieved multi-billion dollar status, the rate at which this novel anticoagulant class has gained share at the expense of generic warfarin has been slower than many analysts had expected.

Emergence of an antidote product is seen as a potential catalyst that could increase usage of the Factor Xa class, with Portola successfully leveraging this dynamic to secure co-funding for its clinical studies from some of the larger pharmaceutical manufacturers who compete in this segment. Portola's recently unveiled Phase III data demonstrates the ability of andexanet alfa to reverse the effect of Eliquis, but studies are also under way with Xarelto, for example (ViewPoints: Portola leverages support from future competitors into successful data for Factor Xa antidote).

With these factors in mind, FirstWord is polling US and EU5-based cardiologists to ascertain whether and how the availability of andexanet alfa would impact their usage of Factor Xa inhibitors. Specifically, we are asking them...

How aware they are of the andexanet alfa development programme?
What percentage of eligible patients they currently treat with a Factor Xa inhibitor?
What percentage of eligible patients they choose NOT to treat with a Factor Xa anticoagulant due to bleeding risk?
By what percentage they would expect treatment of eligible patients with a Factor Xa inhibitor to increase if an effective 'reversal agent' was available?
Theoretically, whether the availability of a reversal agent has a positive impact on your use of a specific Factor Xa inhibitor in favour of others (bearing in mind their slightly different clinical profiles)?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Middle East and Africa Medical Cyclotron Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type ; Capacity ; End User, and Country

  • $ 3000
  • February 2021
  • 81 pages

The Middle East and Africa medical cyclotron market is expected to reach US$ 6.69 million in 2027 from US$ 5.47 million in 2019, it is estimated to grow at a CAGR of 2.6% from 2020 to 2027. The growth ...

  • Middle East
  • Africa
  • Nuclear Imaging Equipment
  • Pharmaceutical
  • Industry analysis
  • Health Expenditure
  • Diagnostic Imaging Density

Global Mesifurane Industry $ 5600 March 2021

Global Strobe Beacons Industry $ 5600 March 2021


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on